Experimental Drug Elamipretide Rescues Infant With Fatal Heart Condition From Transplant List
A newborn with severe Barth syndrome cardiomyopathy showed sustained improvement on elamipretide, potentially avoiding heart transplant entirely.
Summary
Barth syndrome is a rare, often fatal X-linked mitochondrial disease caused by mutations in the TAFAZZIN gene, disrupting cardiolipin synthesis and causing cardiomyopathy, neutropenia, and muscle weakness. No FDA-approved treatments exist. Elamipretide, a mitochondria-targeting peptide that stabilizes cardiolipin, has shown promise in older patients. This case report describes a prenatally diagnosed infant with severe left ventricular non-compaction cardiomyopathy who received elamipretide shortly after birth. The infant showed significant and sustained clinical improvement, moving to inactive status on the heart transplant list with anticipated delisting — a remarkable outcome for a condition with historically poor prognosis.
Detailed Summary
Barth syndrome is an exceptionally rare X-linked mitochondrial disorder caused by pathogenic variants in the TAFAZZIN (TAZ) gene. The resulting defects in mature cardiolipin synthesis disrupt mitochondrial inner membrane integrity, impairing cellular energy production. Affected individuals — almost exclusively male — may develop life-threatening cardiomyopathy, cyclic neutropenia, skeletal myopathy, and growth failure. Despite its severity, no FDA-approved therapies currently exist.
Elamipretide (ELAM) is a first-in-class mitochondria-targeting tetrapeptide that selectively binds and stabilizes cardiolipin within the inner mitochondrial membrane. By restoring cardiolipin's structural role, it supports electron transport chain efficiency and reduces oxidative stress. Pre-clinical models and early clinical studies in adolescents and adults with Barth syndrome have shown improvements in mitochondrial bioenergetics and functional capacity.
This paper presents a particularly compelling case: a prenatally identified infant with Barth syndrome-related severe left ventricular non-compaction cardiomyopathy — a structural cardiac abnormality — who was started on elamipretide very shortly after birth in the setting of clinical heart failure. This represents one of the earliest treatment initiations reported in the literature.
The outcome was striking. The infant demonstrated significant and sustained clinical improvement, progressing to inactive status on the heart transplant waitlist, with eventual delisting anticipated. While causality cannot be firmly established from a single case, the timing and degree of improvement suggest elamipretide may have played a meaningful therapeutic role.
The authors also provide a comprehensive literature review covering Barth syndrome pathophysiology, elamipretide's mechanism of action, and current clinical evidence. This case adds important real-world data supporting earlier intervention and expands the known application of elamipretide to neonates, a population not previously well-represented in clinical studies.
Key Findings
- Infant with prenatally diagnosed Barth syndrome-related LV non-compaction cardiomyopathy started elamipretide shortly after birth.
- Patient achieved sustained clinical improvement and was placed on inactive heart transplant waitlist status.
- Eventual full delisting from transplant list is anticipated — a rare and significant outcome.
- Elamipretide stabilizes cardiolipin and improves mitochondrial bioenergetics in Barth syndrome models.
- No FDA-approved therapies currently exist for Barth syndrome; elamipretide remains investigational.
Methodology
This is a single case report combined with a narrative literature review, not a controlled clinical trial. The patient was identified prenatally and treated with elamipretide in the neonatal period. Clinical outcomes were tracked longitudinally including transplant list status.
Study Limitations
Single case report limits generalizability and precludes causal conclusions. Natural disease variation in Barth syndrome means spontaneous improvement cannot be entirely excluded. Neonatal pharmacokinetics and long-term safety of elamipretide in infants remain incompletely characterized.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.